[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 6, 1974

Drug Spotlight on Anticoagulants

Author Affiliations

Chairman Subcommittee on Hospital-Based Education in Therapeutics American Society for Clinical Pharmacology and Therapeutics Department of Medicine-RG 20, School of Medicine University of Washington Seattle

JAMA. 1974;228(6):734-735. doi:10.1001/jama.1974.03230310044029

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The Drug Spotlight turns on anticoagulants, because the appropriate use of these agents could prevent a substantial number of the 50,000 deaths caused by venous thromboembolism annually in the United States.

Experts may differ on some of the indications for anticoagulant therapy, the method of administration, and the duration of therapy. Nonetheless, it is important to determine how the use of anticoagulants in your hospital measures up to the ideas presented by Dr. Stanford Wessler, on page 757 and the opinions expressed in the other scientific reports presented in the other journals participating in the program.

Listed below are suggestions for studies of anticoagulant therapy. Your pharmacy and therapeutics committee should gather data on one or more of these subjects or on some other aspect of anticoagulation. The analysis of your data might lead to more effective use of anticoagulants and to a reduction in morbidity and mortality from venous